NEWS COMMENTARY

uBiome's questionable business practices are likely to wreak havoc on direct-to-consumer microbiome testing

Published:
May 07, 2019
Coverage:
Emerging Ecosystems in Agrifood and Health More...
Activities:
Incident More...
by Sara Olson
Very important

Unlike recent consumer health pariah Theranos, uBiome has a wealth of scientific and clinical support for its tests. However, the company's recent questionable (and potentially fraudulent) business practices have landed it in hot water with U.S. legal agencies, including the FBI. From overcharging consumers to pressuring doctors into ordering its tests, the company has likely done significant damage to consumers' perceptions of the nascent direct-to-consumer microbiome testing industry. Clients should be aware that any fallout from uBiome's fall from grace will most likely shrink the realistic potential market size for these tests as consumers become increasingly wary of any provider offering similar tests. 

For the original news article, click here .


Further Reading

uBiome and Arivale show the paradox of test-based health services

Case Study | July 03, 2019

In the field of test‑based health services, both uBiome and Arivale were funding front‑runners, gaining $110 million and $53 million, respectively, to date. uBiome specializes in microbiome‑based testing, while Arivale provided a panel of biomarker, genetic, and gut microbiome analysis. Both have ... Not part of subscription

Nebula Genomics prices its direct-to-consumer whole-genome sequencing service at more than two times less than current offerings

News Commentary | February 19, 2020

Nebula launched its WGS offering at $299. Current competitors price their offerings anywhere from $500 to $1,000. Once deemed a luxury only available to research labs and customers who can afford these price points, the further slashing of these prices lowers the barrier to access to a larger ... Not part of subscription

Wastewater-based epidemiology can be an early warning tool for COVID-19 spread

News Commentary | April 01, 2020

A research group from the Cranfield University Water Science Institute has developed a proof‑of‑concept testing device using paper‑based diagnostics to identify genetic material from the SARS‑CoV‑2 virus (which causes COVID‑19 disease) in wastewater, which would indicate the presence of the virus in... To read more, click here.